A Prospective Study of the Relevance of the HLA-G Immune Checkpoint in Cancer Immunotherapy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

281 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-03-10

Study Completion Date

2025-09-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Therapeutic targeting of immune checkpoints PD-1/PD-L1 and/or CTLA-4 is efficient in several solid cancer subtypes, however only some patients do experience clinical benefit from these treatments. One explanation could be that multiple redundant checkpoints are present within the tumor, simultaneously keeping in check the patient's immune response. The immune checkpoint HLA-G is neo-expressed in over 50% of cases in some cancer subtypes and associated with more dismal prognosis. The immunosuppressive effects of HLA-G may result in resistance to current immunotherapy drugs.

The GEIA study explores the impact of HLA-G tumor expression on the efficacy of cancer immunotherapy in solid cancer patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Biomarkers For Immune Checkpoint Inhibitors

NCT04204434

Advanced Cancer Neoplasms

COMPLETED

Integrated Discovery of New Immuno-Molecular Actionable Biomarkers for Tumors With Immune-suppressed Environment

NCT03706625

Non Hodgkin Lymphoma Non Small Cell Lung Cancer Glioma

COMPLETED

Multiepitope Peptide Vaccination in Melanoma

NCT00153569

Metastatic Melanoma

UNKNOWN PHASE2

Immunotherapy of HLA-A2 Positive Stage III/IV Melanoma Patients

NCT00112229

Melanoma

COMPLETED PHASE1

Study of IMC-3G3 in Patients With Tumors That Are Not Responding to Standard Therapies or No Therapy is Available

NCT00768391

Solid Tumors

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Solid Tumor

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients with advanced solid cancer treated with anti-PD(L)1

Adult patients with advanced solid cancer treated with anti-PD(L)1 immunotherapy with or without anti-CTLA4 immunotherapy.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 18 or older
* Social insurance
* Ability to provide signed consent
* Histologically proven solid cancer (non-small cell lung cancer, urothelial carcinoma, renal cell carcinoma, other)
* Advanced and/or metastatic disease not accessible to local treatment
* At least one target lesion according to iRECIST
* Available fixed tumor sample for immunohistochemistry studies
* Treatment with anti-PD(L)1 immunotherapy with or without anti-CTLA4 immunotherapy

Exclusion Criteria

* Women pregnant or breastfeeding
* Inability to consent to this research
* Previous cancer immunotherapy (except BCG instillations for non-muscle infiltrative bladder cancer)
* Patients chronically infected with HIV, HBV or HCV

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No